Biogen (BIIB) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Chair welcomed stockholders and introduced the Board, executive team, and independent auditor present at the meeting.
Outlined the agenda, including voting on proposals and a Q&A session for stockholders.
Board and executive committee updates
Board and executive team members were introduced, highlighting their roles and presence.
Shareholder proposals
Six proposals were presented: election of nine directors, ratification of auditor, advisory vote on executive compensation, amendment for officer exculpation, approval of 2024 Omnibus Plan, and approval of 2024 Employee Stock Purchase Plan.
Board recommended voting in favor of all proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen
- Advances in Alzheimer's, SMA, and immunology pipelines highlight innovation and pivotal trials.BIIB
Stifel 2026 Virtual CNS Forum18 Mar 2026 - Felzartamab targets four kidney indications with phase III trials and a $2B+ AMR market opportunity.BIIB
Leerink Global Healthcare Conference 202610 Mar 2026 - Pipeline expansion and new launches drive growth, with major Alzheimer's and SMA catalysts ahead.BIIB
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs.BIIB
Piper Sandler Virtual Novel Targets in Immunology Symposium13 Feb 2026 - Growth products rose 19% to $3.3B in 2025, offsetting MS declines and driving 2% revenue growth.BIIB
Q4 20256 Feb 2026 - Q2 Non-GAAP EPS up 31% YoY; guidance raised as rare disease and new launches drive growth.BIIB
Q2 20242 Feb 2026 - Growth strategy advances with strong launches, expanded access, and focus on margin improvement.BIIB
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Steady LEQEMBI growth, sub-Q advances, SKYCLARIS expansion, and pipeline diversification drive outlook.BIIB
Jefferies Global Healthcare Conference1 Feb 2026 - LEQEMBI and new launches drive growth, with cost savings and pipeline expansion supporting outlook.BIIB
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026